Clinical Trials Directory

Trials / Conditions / High Grade Serous Carcinoma

High Grade Serous Carcinoma

15 registered clinical trials studyying High Grade Serous Carcinoma — 3 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingRisk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or
NCT06726330
Centre Oscar LambretN/A
WithdrawnPET/MRI in Endometrial Cancer
NCT05390021
Massachusetts General HospitalN/A
RecruitingAdaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or Hig
NCT05080556
University College, LondonPhase 2
TerminatedA Biomarker Screening Protocol for Participants With Solid Tumors
NCT05891197
Lyell Immunopharma, Inc.—
Active Not RecruitingCombination of Olaparib and Navitoclax in Women with HGSC and TNBC
NCT05358639
Sunnybrook Health Sciences CentrePhase 1
TerminatedA Study to Investigate LYL797 in Adults With Solid Tumors
NCT05274451
Lyell Immunopharma, Inc.Phase 1
UnknownLongitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
NCT05537844
Liz-Anne Lewsley—
TerminatedBrUOG 390: Neoadjuvant Treatment With Talazoparib
NCT04598321
Brown UniversityPhase 1
CompletedRole of the ATP7A Transporter in Ovarian Cancer
NCT05490407
University Medical Centre LjubljanaN/A
TerminatedA Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
NCT03824704
pharmaand GmbHPhase 2
UnknownNon-coding RNA in the Exosome of the Epithelia Ovarian Cancer
NCT03738319
Lei Li—
CompletedCompare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of M
NCT03593681
Boston Scientific Corporation—
UnknownBortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer P
NCT03509246
Seoul National University HospitalPhase 2
CompletedCombination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
NCT03462342
University of PennsylvaniaPhase 2
RecruitingMulti-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC
NCT04846933
Turku University HospitalN/A